A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 14,168,116 shares of IONS stock, worth $540 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
14,168,116
Previous 12,639,684 12.09%
Holding current value
$540 Million
Previous $602 Million 5.78%
% of portfolio
0.34%
Previous 0.38%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.06 - $51.86 $61.2 Million - $79.3 Million
1,528,432 Added 12.09%
14,168,116 $568 Million
Q2 2024

Aug 14, 2024

SELL
$36.45 - $47.7 $24.7 Million - $32.3 Million
-677,428 Reduced 5.09%
12,639,684 $602 Million
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $4.86 Million - $6.19 Million
115,659 Added 0.88%
13,317,112 $577 Million
Q4 2023

Feb 14, 2024

BUY
$43.39 - $51.63 $3.4 Million - $4.05 Million
78,398 Added 0.6%
13,201,453 $668 Million
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $1.51 Million - $1.85 Million
39,328 Added 0.3%
13,123,055 $595 Million
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $683,486 - $852,734
19,680 Added 0.15%
13,083,727 $537 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $46.5 Million - $57.1 Million
1,385,788 Added 11.87%
13,064,047 $467 Million
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $19.4 Million - $24.3 Million
521,564 Added 4.67%
11,678,259 $441 Million
Q3 2022

Nov 14, 2022

BUY
$36.54 - $48.66 $408 Million - $543 Million
11,156,695 New
11,156,695 $493 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.41B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track T. Rowe Price Investment Management, Inc. Portfolio

Follow T. Rowe Price Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.